TY - BOOK AU - Parikh, Vicky TI - Study protocol for a telephone-based smoking cessation randomized controlled trial in the lung cancer screening setting: The lung screening, tobacco, and health trial SN - 1551-7144 PY - 2019/// KW - *Early Detection of Cancer KW - *Lung Neoplasms/di [Diagnosis] KW - *Smoking Cessation/mt [Methods] KW - Aged KW - Aged, 80 and over KW - Female KW - Humans KW - Lung Neoplasms/dg [Diagnostic Imaging] KW - Lung/dg [Diagnostic Imaging] KW - Male KW - Middle Aged KW - Randomized Controlled Trials as Topic KW - Telephone KW - Tomography, X-Ray Computed KW - MedStar Shah Medical Group KW - Population Health KW - Journal Article N2 - Copyright (c) 2019 Elsevier Inc. All rights reserved; Lung cancer mortality can be reduced by 20% via low dose CT lung cancer screening (LCS) and treatment of early-stage disease. Providing tobacco use treatment to high risk cigarette smokers in the LCS setting may result in health benefits beyond the impact of LCS. As one of the nine trials in the National Cancer Institute's Smoking Cessation at Lung Examination (SCALE) collaboration, the goal of the Lung Screening, Tobacco, and Health (LSTH) trial is to develop a scalable and cost-effective cessation intervention for subsequent implementation by LCS programs. Guided by the RE-AIM Framework, the LSTH trial is a two-arm RCT (N=1330) enrolling English- and Spanish-speaking smokers registered for LCS at one of seven collaborating sites. Participants are randomly assigned to Usual Care (UC; three proactive telephone counseling sessions/two weeks of nicotine patches) vs. Intensive Telephone Counseling (ITC; eight proactive sessions/eight weeks of nicotine patches, plus discussion of the LCS results to increase motivation to quit). Telephone counseling is provided by tobacco treatment specialists. To increase continuity of care, referring physicians are notified of participant enrollment and smoking status following the intervention. Outcomes include: 1) self-reported 7-day, 30-day, and sustained abstinence, and biochemically-verified at 3-, 6-, and 12-months post-randomization, 2) reach and engagement of the interventions, and 3) cost-effectiveness of the interventions. The Cancer Intervention and Surveillance Modeling Network (CISNET) will model long-term impacts of six SCALE trials on the cost per life year saved, quality-adjusted life years saved, lung cancer mortality reduction, and population mortality. CLINICAL TRIALS REGISTRATION: The trial is registered at clinical trials.gov: NCT03200236 UR - https://dx.doi.org/10.1016/j.cct.2019.05.006 ER -